Empresa TrovaGene Inc Nasdaq
Acciones
US8972384080
Biotecnología e investigación médica
Resumen de negocios
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Novel Therapies for Cancers
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +26,42 % |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +26,42 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 04/03/13 |
James Levine
DFI | Director of Finance/CFO | 53 | 12/07/21 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 11/01/22 |
Chief Tech/Sci/R&D Officer | - | 31/01/23 | |
Vicki Kelemen
COO | Chief Operating Officer | - | 01/01/15 |
Charles Monahan
LAW | General Counsel | - | 11/01/22 |
Brigitte Lindsay
PRN | Corporate Officer/Principal | - | 01/01/12 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 22/04/20 |
Gary Pace
BRD | Director/Board Member | 76 | 22/04/20 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 04/03/13 |
Lâle White
BRD | Director/Board Member | 68 | 22/04/20 |
Mani Mohindru
BRD | Director/Board Member | 52 | 10/06/21 |
Rodney Markin
CHM | Chairman | 67 | 19/02/14 |
Renee Tannenbaum
BRD | Director/Board Member | 72 | 10/06/21 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 44 724 591 | 41 348 436 ( 92,45 %) | 0 | 92,33 % |
Acción B | 0 | 60 600 | 0 | 0 |
Información de la empresa
Cardiff Oncology, Inc.
11055 Flintkote Avenue
92121, San Diego
+858 952 7570
http://www.cardiffoncology.comSector
Varia. 1 de ene. | Capi. | |
---|---|---|
-0,09 % | 42,12 mil M | |
+49,62 % | 42,05 mil M | |
-4,96 % | 29,18 mil M | |
+11,18 % | 26,02 mil M | |
-21,95 % | 18,9 mil M | |
+8,61 % | 13,21 mil M | |
+24,73 % | 12,17 mil M | |
+28,31 % | 12,16 mil M | |
-6,26 % | 11,42 mil M |